Blue test tubes arranged in a line, disappearing into the background

Drug news

NICE rejects Iluvien(Alimera Sciences)for DME treatment

Read time: 1 mins

Last updated:8th Aug 2012

Published:8th Aug 2012

Source: Pharmawand

NICE (The National Institute for Health and Clinical Excellence) has now released a draft recommendation that does not back the use of the sustained-release intravitreal implant for the treatment of visual loss caused by chronic Diabetic Macular Edema (DME), NICE did not find the treatment cost-effective. This is a draft appraisal, and NICE expects to issue its final guidance in November. According to Bloomberg, NICE stated that Alimera "underestimated the incremental cost-effectiveness" of Iluvien, adding that: "Unfortunately in this case, the [independent Appraisal Committee] agreed that the evidence provided could not support a positive recommendation

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Abbott initiates clinical study to evaluate the use of its deep brain stimulation system to manage severe depression.

Abbott announced it has initiated a pivotal clinical trial, called the TRANSCEND study, to evaluate the use of the company's deep brain stimulation (DBS) system to manage treatment-resistant depression (TRD), a form of major depressive disorder.

2 mins

Drug news

Positive results from phase III trial of Nucala (mepolizumab) announced in COPD.-GSK

GSK plc announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5) in adults with chronic obstructive pulmonary disease (COPD).

1 min

Drug news

Roche presents new 48-week data for the Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib from the phase II FENopta open-label extension (OLE) study at the ECTRIMS conference.

Roche presents new 48-week data for the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib from the Phase II FENopta open-label extension (OLE) study at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark on 18 September 2024.

2 min

See all news